Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting
GALECTIN (NASDAQ: GALT) Delayed: 3.71 +0.03 (0.82%)
Previous Close $3.68    52 Week High $3.05 
Open $3.73    52 Week Low $0.49 
Day High $3.79    P/E N/A 
Day Low $3.69    EPS $-1.32 
Volume 171,131